{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:48:23Z","timestamp":1724485703080},"reference-count":98,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMM"],"published-print":{"date-parts":[[2019,10,11]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Papillary thyroid microcarcinoma (PTMC) is defined by the World Health\nOrganization as papillary cancer measuring 10 mm or less in diameter. Generally,\nPTMC shows an indolent clinical behavior with a good prognosis, although a minority of\nPTMC is characterized by an aggressive course. However, efforts to identify this\naggressive subset of PTMC after surgery remain inconclusive.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Several oncogenic pathways have been identified in thyroid cancer and have been\napplied translationally to improve prognosis and clinical management. In particular, the\nBRAFV600E mutation was found more frequently in large, aggressive, recurrent and\nadvanced tumors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>We aimed at reviewing studies on BRAFV600E mutation as a prognostic factor in PTMC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566524019666190717161359","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T18:24:09Z","timestamp":1563992649000},"page":"665-672","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["BRAF Status in Papillary Microcarcinomas of the Thyroid Gland: a Brief Review"],"prefix":"10.2174","volume":"19","author":[{"given":"Antonio","family":"Ieni","sequence":"first","affiliation":[{"name":"Department of Human Pathology \"Gaetano Barresi\" - Section of Pathological Anatomy, A.O.U. Polyclinic G.Martino, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Vita","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Cardia","sequence":"additional","affiliation":[{"name":"Department of Human Pathology \"Gaetano Barresi\" - Section of Pathological Anatomy, A.O.U. Polyclinic G.Martino, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Giuffr\u00e9","sequence":"additional","affiliation":[{"name":"Department of Human Pathology \"Gaetano Barresi\" - Section of Pathological Anatomy, A.O.U. Polyclinic G.Martino, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Benvenga","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Tuccari","sequence":"additional","affiliation":[{"name":"Department of Human Pathology \"Gaetano Barresi\" - Section of Pathological Anatomy, A.O.U. Polyclinic G.Martino, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12020-018-1681-6","volume":"62","author":"Salamanca-Fern\u00e1ndez E.","year":"2018","unstructured":"Salamanca-Fern\u00e1ndez E.; Rodriguez-Barranco M.; Chang-Chan Y.L.; Thyroid Cancer Epidemiology in South Spain: a population-based time trend study. Endocrine 2018,62(2),423-431","journal-title":"Endocrine"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11154-016-9398-4","volume":"17","author":"Ieni A.","year":"2016","unstructured":"Ieni A.; Barresi V.; Cardia R.; The micropapillary\/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution. Rev Endocr Metab Disord 2016,17(4),521-527","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11154-018-9474-z","volume":"19","author":"Vita R.","year":"2018","unstructured":"Vita R.; Ieni A.; Tuccari G.; Benvenga S.; The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord 2018,19(4),301-309","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fendo.2017.00337","volume":"8","author":"Ieni A.","year":"2017","unstructured":"Ieni A.; Vita R.; Magliolo E.; One-third of an archivial series of papillary thyroid cancer (Years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable tumor-node-metastasis staging. Front Endocrinol (Lausanne) 2017,8,337","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CCO.0000000000000148","volume":"27","author":"Vigneri R.","year":"2015","unstructured":"Vigneri R.; Malandrino P.; Vigneri P.; The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 2015,27(1),1-7","journal-title":"Curr Opin Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"Siegel R.L.","year":"2018","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2018. CA Cancer J Clin 2018,68(1),7-30","journal-title":"CA Cancer J Clin"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"Miller K.D.","year":"2016","unstructured":"Miller K.D.; Siegel R.L.; Lin C.C.; Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016,66(4),271-289","journal-title":"CA Cancer J Clin"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1066896913517394","volume":"22","author":"Soares P.","year":"2014","unstructured":"Soares P.; Celestino R.; Gaspar da Rocha A.; Sobrinho-Sim\u00f5es M.; Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic? Int J Surg Pathol 2014,22(2),113-119","journal-title":"Int J Surg Pathol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1089\/thy.2010.0137","volume":"21","author":"Hughes D.T.","year":"2011","unstructured":"Hughes D.T.; Haymart M.R.; Miller B.S.; Gauger P.G.; Doherty G.M.; The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 2011,21(3),231-236","journal-title":"Thyroid"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12957-018-1501-8","volume":"16","author":"Kaliszewski K.","year":"2018","unstructured":"Kaliszewski K.; Zubkiewicz-Kucharska A.; Kie\u0142b P.; Maksymowicz J.; Krawczyk A.; Krawiec O.; Comparison of the prevalence of incidental and non-incidental papillary thyroid microcarcinoma during 2008-2016: a single-center experience. World J Surg Oncol 2018,16(1),202","journal-title":"World J Surg Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1002\/cncr.30201","volume":"122","author":"Lubitz C.C.","year":"2016","unstructured":"Lubitz C.C.; Sosa J.A.; The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. Cancer 2016,122(24),3754-3759","journal-title":"Cancer"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ejso.2017.03.004","volume":"44","author":"Ito Y.","year":"2018","unstructured":"Ito Y.; Miyauchi A.; Oda H.; Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol 2018,44(3),307-315","journal-title":"Eur J Surg Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12022-018-9546-3","volume":"29","author":"Shafique K.","year":"2018","unstructured":"Shafique K.; LiVolsi VA, Montone K, Baloch ZW. Papillary Thyroid Microcarcinoma: Reclassification to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): a Retrospective Clinicopathologic Study. Endocr Pathol 2018,29(4),339-345","journal-title":"Endocr Pathol"},{"key":"ref=14","author":"Lloyd R.V.","year":"2017","unstructured":"Lloyd R.V.; Osamura R.Y.; Kloppel G.; Rosai J.;  WHO classification of tumours of the endocrine organs 2017","journal-title":"WHO classification of tumours of the endocrine organs"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/1759-7714.12858","volume":"9","author":"Huang M.","year":"2018","unstructured":"Huang M.; Yan C.; Wei H.; Lv Y.; Ling R.; Clinicopathological characteristics and prognosis of thyroid cancer in northwest China: A population-based retrospective study of 2490 patients. Thorac Cancer 2018,9(11),1453-1460","journal-title":"Thorac Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41574-018-0080-7","volume":"14","author":"Wang T.S.","year":"2018","unstructured":"Wang T.S.; Sosa J.A.; Thyroid surgery for differentiated thyroid cancer - recent advances and future directions. Nat Rev Endocrinol 2018,14(11),670-683","journal-title":"Nat Rev Endocrinol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.18632\/oncotarget.12698","volume":"8","author":"Yi D.","year":"2017","unstructured":"Yi D.; Song P.; Huang T.; Tang X.; Sang J.; A meta-analysis on the effect of operation modes on the recurrence of papillary thyroid microcarcinoma. Oncotarget 2017,8(4),7148-7156","journal-title":"Oncotarget"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/CCO.0b013e328359feea","volume":"25","author":"Wu L.S.","year":"2013","unstructured":"Wu L.S.; Milan S.A.; Management of microcarcinomas (papillary and medullary) of the thyroid. Curr Opin Oncol 2013,25(1),27-32","journal-title":"Curr Opin Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"Haugen B.R.","year":"2016","unstructured":"Haugen B.R.; Alexander E.K.; Bible K.C.; 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016,26(1),1-133","journal-title":"Thyroid"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/SLA.0b013e318230036d","volume":"254","author":"Yu X.M.","year":"2011","unstructured":"Yu X.M.; Wan Y.; Sippel R.S.; Chen H.; Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 2011,254(4),653-660","journal-title":"Ann Surg"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.ejso.2018.08.004","volume":"44","author":"Zheng W.","year":"2018","unstructured":"Zheng W.; Li J.; Lv P.; Chen Z.; Fan P.; Treatment efficacy between total thyroidectomy and lobectomy for patients with papillary thyroid microcarcinoma: A systemic review and meta-analysis. Eur J Surg Oncol 2018,44(11),1679-1684","journal-title":"Eur J Surg Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00405-016-4302-0","volume":"274","author":"Liu L.S.","year":"2017","unstructured":"Liu L.S.; Liang J.; Li J.H.; The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Otorhinolaryngol 2017,274(3),1327-1338","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/thy.2015.0375","volume":"26","author":"Jeon M.J.","year":"2016","unstructured":"Jeon M.J.; Kim W.G.; Choi Y.M.; Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas. Thyroid 2016,26(1),161-168","journal-title":"Thyroid"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/RLU.0b013e318279bc65","volume":"38","author":"Ardito G.","year":"2013","unstructured":"Ardito G.; Revelli L.; Giustozzi E.; Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med 2013,38(1),25-28","journal-title":"Clin Nucl Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10147-017-1170-6","volume":"23","author":"Zhi J.","year":"2018","unstructured":"Zhi J.; Zhao J.; Gao M.; Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases. Int J Clin Oncol 2018,23(1),59-65","journal-title":"Int J Clin Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3892\/mco.2016.1085","volume":"6","author":"Tao Y.","year":"2017","unstructured":"Tao Y.; Wang C.; Li L.; Clinicopathological features for predicting central and lateral lymph node metastasis in papillary thyroid microcarcinoma: Analysis of 66 cases that underwent central and lateral lymph node dissection. Mol Clin Oncol 2017,6(1),49-55","journal-title":"Mol Clin Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jss.2017.08.007","volume":"221","author":"Xu Y.","year":"2018","unstructured":"Xu Y.; Xu L.; Wang J.; Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution. J Surg Res 2018,221,128-134","journal-title":"J Surg Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1210\/jc.2013-2118","volume":"99","author":"Mehanna H.","year":"2014","unstructured":"Mehanna H.; Al-Maqbili T.; Carter B.; Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J Clin Endocrinol Metab 2014,99(8),2834-2843","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.clon.2016.12.009","volume":"29","author":"Tarasova V.D.","year":"2017","unstructured":"Tarasova V.D.; Tuttle R.M.; Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma. Clin Oncol (R Coll Radiol) 2017,29(5),290-297","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/01.SLA.0000055273.58908.19","volume":"237","author":"Wada N.","year":"2003","unstructured":"Wada N.; Duh Q.Y.; Sugino K.; Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003,237(3),399-407","journal-title":"Ann Surg"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s12020-018-1523-6","volume":"59","author":"Tam A.A.","year":"2018","unstructured":"Tam A.A.; Ozdemir D.; Ayd\u0131n C.; Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer. Endocrine 2018,59(3),565-572","journal-title":"Endocrine"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4158\/EP.13.5.521","volume":"13","author":"Hay I.D.","year":"2007","unstructured":"Hay I.D.; Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract 2007,13(5),521-533","journal-title":"Endocr Pract"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00268-009-0303-0","volume":"34","author":"Ito Y.","year":"2010","unstructured":"Ito Y.; Miyauchi A.; Inoue H.; An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010,34(1),28-35","journal-title":"World J Surg"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00595-009-4034-5","volume":"40","author":"Sugitani I.","year":"2010","unstructured":"Sugitani I.; Fujimoto Y.; Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence. Surg Today 2010,40(3),199-215","journal-title":"Surg Today"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2174\/1389202915999140404100958","volume":"15","author":"Benvenga S.","year":"2014","unstructured":"Benvenga S.; Koch C.A.; Molecular pathways associated with aggressiveness of papillary thyroid cancer. Curr Genomics 2014,15(3),162-170","journal-title":"Curr Genomics"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/his.13380","volume":"72","author":"Acquaviva G.","year":"2018","unstructured":"Acquaviva G.; Visani M.; Repaci A.; Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. Histopathology 2018,72(1),6-31","journal-title":"Histopathology"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1080\/15384101.2015.1049786","volume":"14","author":"Costa V.","year":"2015","unstructured":"Costa V.; Esposito R.; Pallante P.; Ciccodicola A.; Fusco A.; The \u201cnext-generation\u201d knowledge of papillary thyroid carcinoma. Cell Cycle 2015,14(13),2018-2021","journal-title":"Cell Cycle"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/onc.2011.44","volume":"30","author":"Knauf J.A.","year":"2011","unstructured":"Knauf J.A.; Sartor M.A.; Medvedovic M.; Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF\u03b2 signaling. Oncogene 2011,30(28),3153-3162","journal-title":"Oncogene"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.yexmp.2018.11.002","volume":"105","author":"Ahmad F.","year":"2018","unstructured":"Ahmad F.; Nathani R.; Venkat J.; Molecular evaluation of BRAF gene mutation in thyroid tumors: Significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of aggressive disease. Exp Mol Pathol 2018,105(3),380-386","journal-title":"Exp Mol Pathol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.21037\/gs.2017.11.07","volume":"7","author":"Ferrari S.M.","year":"2018","unstructured":"Ferrari S.M.; Fallahi P.; Ruffilli I.; Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surg 2018,7(Suppl. 1),S19-S29","journal-title":"Gland Surg"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1158\/0008-5472.CAN-06-0739","volume":"66","author":"Mesa C.","year":"2006","unstructured":"Mesa C.; Mirza M.; Mitsutake N.; Conditional activation of RET\/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 2006,66(13),6521-6529","journal-title":"Cancer Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1210\/me.2003-0041","volume":"17","author":"Wang J.","year":"2003","unstructured":"Wang J.; Knauf J.A.; Basu S.; Conditional expression of RET\/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol 2003,17(7),1425-1436","journal-title":"Mol Endocrinol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S1726-4901(10)70025-3","volume":"73","author":"Tang K.T.","year":"2010","unstructured":"Tang K.T.; Lee C.H.; BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010,73(3),113-128","journal-title":"J Chin Med Assoc"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ecl.2008.01.001","volume":"37","author":"Paes J.E.","year":"2008","unstructured":"Paes J.E.; Ringel M.D.; Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am [viii-ix.]2008,37(2),375-387","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4161\/cc.10.1.14362","volume":"10","author":"Nowicki T.S.","year":"2011","unstructured":"Nowicki T.S.; Zhao H.; Darzynkiewicz Z.; Downregulation of uPAR inhibits migration, invasion, proliferation, FAK\/PI3K\/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011,10(1),100-107","journal-title":"Cell Cycle"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1210\/en.2005-0280","volume":"147","author":"Mitsutake N.","year":"2006","unstructured":"Mitsutake N.; Miyagishi M.; Mitsutake S.; BRAF mediates RET\/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET\/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 2006,147(2),1014-1019","journal-title":"Endocrinology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1530\/ERC-14-0531","volume":"22","author":"Li F.","year":"2015","unstructured":"Li F.; Chen G.; Sheng C.; BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer 2015,22(2),159-168","journal-title":"Endocr Relat Cancer"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1089\/thy.2015.0391","volume":"26","author":"Chen Y.","year":"2016","unstructured":"Chen Y.; Sadow P.M.; Suh H.; BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Thyroid 2016,26(2),248-255","journal-title":"Thyroid"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/eci.12577","volume":"46","author":"Wang Z.","year":"2016","unstructured":"Wang Z.; Chen J.Q.; Liu J.L.; Qin X.G.; Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Clin Invest 2016,46(2),146-157","journal-title":"Eur J Clin Invest"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2174\/1389202918666170105094459","volume":"18","author":"Rodrigues A.C.","year":"2017","unstructured":"Rodrigues A.C.; Penna G.; Rodrigues E.; Castro P.; Sobrinho-Sim\u00f5es M.; Soares P.; The genetics of papillary microcarcinomas of the thyroid: Diagnostic and prognostic implications. Curr Genomics 2017,18(3),244-254","journal-title":"Curr Genomics"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/thy.2006.0305","volume":"17","author":"Ugolini C.","year":"2007","unstructured":"Ugolini C.; Giannini R.; Lupi C.; Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007,17(5),381-388","journal-title":"Thyroid"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1677\/ERC-07-0212","volume":"15","author":"Frasca F.","year":"2008","unstructured":"Frasca F.; Nucera C.; Pellegriti G.; BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008,15(1),191-205","journal-title":"Endocr Relat Cancer"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/his.12233","volume":"63","author":"Mussazhanova Z.","year":"2013","unstructured":"Mussazhanova Z.; Matsuda K.; Naruke Y.; Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status. Histopathology 2013,63(5),726-734","journal-title":"Histopathology"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1210\/jc.2011-3135","volume":"97","author":"Lee S.T.","year":"2012","unstructured":"Lee S.T.; Kim S.W.; Ki C.S.; Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab 2012,97(7),2299-2306","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1210\/jc.2012-2444","volume":"97","author":"Joo J.Y.","year":"2012","unstructured":"Joo J.Y.; Park J.Y.; Yoon Y.H.; Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab 2012,97(11),3996-4003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1089\/thy.2011.0123","volume":"22","author":"Jung C.K.","year":"2012","unstructured":"Jung C.K.; Im S.Y.; Kang Y.J.; Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid 2012,22(8),791-797","journal-title":"Thyroid"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1677\/JME-08-0063","volume":"41","author":"Lin X.","year":"2008","unstructured":"Lin X.; Finkelstein S.D.; Zhu B.; Silverman J.F.; Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol 2008,41(4),195-203","journal-title":"J Mol Endocrinol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/modpathol.2008.51","volume":"21","author":"Min H.S.","year":"2008","unstructured":"Min H.S.; Choe G.; Kim S.W.; S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol 2008,21(6),748-755","journal-title":"Mod Pathol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1210\/jc.2010-0337","volume":"95","author":"Basolo F.","year":"2010","unstructured":"Basolo F.; Torregrossa L.; Giannini R.; Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 2010,95(9),4197-4205","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1245\/s10434-010-1129-6","volume":"17","author":"Lin K.L.","year":"2010","unstructured":"Lin K.L.; Wang O.C.; Zhang X.H.; Dai X.X.; Hu X.Q.; Qu J.M.; The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 2010,17(12),3294-3300","journal-title":"Ann Surg Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12020-012-9651-x","volume":"42","author":"Kurtulmus N.","year":"2012","unstructured":"Kurtulmus N.; Duren M.; Ince U.; BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 2012,42(2),404-410","journal-title":"Endocrine"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1089\/thy.2013.0036","volume":"23","author":"Lim J.Y.","year":"2013","unstructured":"Lim J.Y.; Hong S.W.; Lee Y.S.; Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid 2013,23(11),1423-1430","journal-title":"Thyroid"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110868","volume":"9","author":"Park A.Y.","year":"2014","unstructured":"Park A.Y.; Son E.J.; Kim J.A.; Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. PLoS One 2014,9(10)","journal-title":"PLoS One"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.3892\/ol.2015.3119","volume":"9","author":"Yu L.","year":"2015","unstructured":"Yu L.; Ma L.; Tu Q.; Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules. Oncol Lett 2015,9(6),2633-2638","journal-title":"Oncol Lett"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.humpath.2015.06.018","volume":"46","author":"Choi Y.W.","year":"2015","unstructured":"Choi Y.W.; Kim Y.H.; Lee J.; Soh E.Y.; Park T.J.; Kim J.H.; Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma. Hum Pathol 2015,46(10),1557-1565","journal-title":"Hum Pathol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/1477-7819-11-291","volume":"11","author":"Choi S.Y.","year":"2013","unstructured":"Choi S.Y.; Park H.; Kang M.K.; The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol 2013,11,291","journal-title":"World J Surg Oncol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1365-2265.2006.02605.x","volume":"65","author":"Kim T.Y.","year":"2006","unstructured":"Kim T.Y.; Kim W.B.; Rhee Y.S.; The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006,65(3),364-368","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/cen.12386","volume":"80","author":"Walczyk A.","year":"2014","unstructured":"Walczyk A.; Kowalska A.; Kowalik A.; The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf) 2014,80(6),899-904","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3892\/ijo.25.6.1729","volume":"25","author":"Sedliarou I.","year":"2004","unstructured":"Sedliarou I.; Saenko V.; Lantsov D.; The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 2004,25(6),1729-1735","journal-title":"Int J Oncol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1245\/s10434-008-0233-3","volume":"16","author":"Lee X.","year":"2009","unstructured":"Lee X.; Gao M.; Ji Y.; Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009,16(2),240-245","journal-title":"Ann Surg Oncol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1245\/s10434-012-2851-z","volume":"20","author":"Zheng X.","year":"2013","unstructured":"Zheng X.; Wei S.; Han Y.; Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 2013,20(7),2266-2273","journal-title":"Ann Surg Oncol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/cncy.21258","volume":"121","author":"Rossi E.D.","year":"2013","unstructured":"Rossi E.D.; Martini M.; Capodimonti S.; BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol 2013,121(6),291-297","journal-title":"Cancer Cytopathol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1148\/radiol.2533090471","volume":"253","author":"Kwak J.Y.","year":"2009","unstructured":"Kwak J.Y.; Kim E.K.; Chung W.Y.; Moon H.J.; Kim M.J.; Choi J.R.; Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 2009,253(3),854-860","journal-title":"Radiology"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1245\/s10434-010-1129-6","volume":"17","author":"Lin K.L.","year":"2010","unstructured":"Lin K.L.; Wang O.C.; Zhang X.H.; Dai X.X.; Hu X.Q.; Qu J.M.; The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 2010,17(12),3294-3300","journal-title":"Ann Surg Oncol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1089\/thy.2011.0107","volume":"22","author":"Marchetti I.","year":"2012","unstructured":"Marchetti I.; Iervasi G.; Mazzanti C.M.; Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid 2012,22(3),292-298","journal-title":"Thyroid"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12020-013-0029-5","volume":"45","author":"Barbaro D.","year":"2014","unstructured":"Barbaro D.; Incensati R.M.; Materazzi G.; The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine 2014,45(3),462-468","journal-title":"Endocrine"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.7314\/APJCP.2012.13.4.1267","volume":"13","author":"Zhou Y.L.","year":"2012","unstructured":"Zhou Y.L.; Zhang W.; Gao E.L.; Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Asian Pac J Cancer Prev 2012,13(4),1267-1272","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12022-015-9374-7","volume":"26","author":"Pyo J.S.","year":"2015","unstructured":"Pyo J.S.; Sohn J.H.; Kang G.; BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma. Endocr Pathol 2015,26(3),211-217","journal-title":"Endocr Pathol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/jclinpath-2017-204367","volume":"70","author":"O\u2019Brien O.","year":"2017","unstructured":"O\u2019Brien O.; Lyons T.; Murphy S.; Feeley L.; Power D.; Heffron C.C.B.B.; BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. J Clin Pathol 2017,70(11),935-940","journal-title":"J Clin Pathol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.prp.2017.09.001","volume":"214","author":"Chen D.","year":"2018","unstructured":"Chen D.; Qi W.; Zhang P.; Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma. Pathol Res Pract 2018,214(2),303-307","journal-title":"Pathol Res Pract"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"464","DOI":"10.2353\/jmoldx.2007.060191","volume":"9","author":"Spittle C.","year":"2007","unstructured":"Spittle C.; Ward M.R.; Nathanson K.L.; Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 2007,9(4),464-471","journal-title":"J Mol Diagn"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2050-7771-1-3","volume":"1","author":"Huang T.","year":"2013","unstructured":"Huang T.; Zhuge J.; Zhang W.W.; Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res 2013,1(1),3","journal-title":"Biomark Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","volume":"122","author":"Capper D.","year":"2011","unstructured":"Capper D.; Preusser M.; Habel A.; Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011,122(1),11-19","journal-title":"Acta Neuropathol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/PAS.0b013e318246b527","volume":"36","author":"Koperek O.","year":"2012","unstructured":"Koperek O.; Kornauth C.; Capper D.; Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012,36(6),844-850","journal-title":"Am J Surg Pathol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","volume":"123","author":"Capper D.","year":"2012","unstructured":"Capper D.; Berghoff A.S.; Magerle M.; Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012,123(2),223-233","journal-title":"Acta Neuropathol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/00313020801911512","volume":"40","author":"Tan Y.H.","year":"2008","unstructured":"Tan Y.H.; Liu Y.; Eu K.W.; Detection of BRAF V600E mutation by pyrosequencing. Pathology 2008,40(3),295-298","journal-title":"Pathology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/PAI.0000000000000308","volume":"25","author":"Kim W.Y.","year":"2017","unstructured":"Kim W.Y.; Kim H.; Hwang T.S.; Oh S.Y.; Comparison between real-time PCR and pyrosequencing for detection of BRAF V600E mutation in thyroid fine-needle aspirates. Appl Immunohistochem Mol Morphol 2017,25(5),358-365","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1136\/jcp.2006.040105","volume":"60","author":"Rowe L.R.","year":"2007","unstructured":"Rowe L.R.; Bentz B.G.; Bentz J.S.; Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol 2007,60(11),1211-1215","journal-title":"J Clin Pathol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1210\/jc.2003-032221","volume":"89","author":"Salvatore G.","year":"2004","unstructured":"Salvatore G.; Giannini R.; Faviana P.; Analysis of BRAF point mutation and RET\/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004,89(10),5175-5180","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1373\/clinchem.2006.070169","volume":"52","author":"James M.R.","year":"2006","unstructured":"James M.R.; Dumeni T.; Stark M.S.; Rapid screening of 4000 individuals for germ-line variations in the BRAF gene. Clin Chem 2006,52(9),1675-1678","journal-title":"Clin Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2353\/jmoldx.2007.060072","volume":"9","author":"Kim I.J.","year":"2007","unstructured":"Kim I.J.; Kang H.C.; Jang S.G.; Ahn S.A.; Yoon H.J.; Park J.G.; Development and applications of a BRAF oligonucleotide microarray. J Mol Diagn 2007,9(1),55-63","journal-title":"J Mol Diagn"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12022-018-9532-9","volume":"29","author":"Baloch Z.","year":"2018","unstructured":"Baloch Z.; Mete O.; Asa S.L.; Immunohistochemical Biomarkers in Thyroid Pathology. Endocr Pathol 2018,29(2),91-112","journal-title":"Endocr Pathol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/PAT.0000000000000119","volume":"46","author":"Dvorak K.","year":"2014","unstructured":"Dvorak K.; Aggeler B.; Palting J.; McKelvie P.; Ruszkiewicz A.; Waring P.; Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology 2014,46(6),509-517","journal-title":"Pathology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/09674845.2019.1592885","volume":"76","author":"Orchard G.E.","year":"2019","unstructured":"Orchard G.E.; Wojcik K.; Rickaby W.; Immunohistochemical detection of V600E BRAF mutation is a useful primary screening tool for malignant melanoma. Br J Biomed Sci 2019,76(2),77-82","journal-title":"Br J Biomed Sci"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3892\/ol.2019.10131","volume":"17","author":"Zhao J.","year":"2019","unstructured":"Zhao J.; Liu P.; Yu Y.; Comparison of diagnostic methods for the detection of a BRAF mutation in papillary thyroid cancer. Oncol Lett 2019,17(5),4661-4666","journal-title":"Oncol Lett"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/cyt.12690","volume":"30","author":"Straccia P.","year":"2019","unstructured":"Straccia P.; Brunelli C.; Rossi E.D.; The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology. Cytopathology 2019,30(5),460-467","journal-title":"Cytopathology"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1245\/s10434-018-6460-3","volume":"25","author":"Kim J.K.","year":"2018","unstructured":"Kim J.K.; Seong C.Y.; Bae I.E.; Comparison of immunohistochemistry and direct sequencing methods for identification of the BRAF mutation in papillary thyroid carcinoma. Ann Surg Oncol 2018,25(6),1775-1781","journal-title":"Ann Surg Oncol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"74897","DOI":"10.18632\/oncotarget.20451","volume":"8","author":"Szymonek M.","year":"2017","unstructured":"Szymonek M.; Kowalik A.; Kopczy\u0144ski J.; Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma. Oncotarget 2017,8(43),74897-74909","journal-title":"Oncotarget"}],"container-title":["Current Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T18:47:55Z","timestamp":1574016475000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173611\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":98,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,10,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566524019666190717161359","relation":{},"ISSN":["1566-5240"],"issn-type":[{"value":"1566-5240","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}